Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.59 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.48 |
| ▸ | FDPS | P14324 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.47 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.47 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10935964 | 1.00 | CA1 (0.59) | CA1ACE2EPHX1FFAR1FFAR4 | |
| SCHEMBL8197428 | 1.00 | CA1 (0.59) | CA1ACE2EPHX1FFAR1FFAR4 | |
| SCHEMBL5423239 | 1.00 | CA1 (0.59) | CA1ACE2EPHX1FFAR1FFAR4 | |
| SCHEMBL12326336 | 1.00 | CA1 (0.59) | CA1ACE2EPHX1FFAR1FFAR4 | |
| SCHEMBL10866301 | 1.00 | CA1 (0.59) | CA1ACE2EPHX1FFAR1FFAR4 | |
| SCHEMBL2348891 | 1.00 | CA1 (0.59) | CA1ACE2EPHX1FFAR1FFAR4 | |
| SCHEMBL23857835 | 1.00 | CA1 (0.59) | CA1ACE2EPHX1FFAR1FFAR4 | |
| SCHEMBL13854594 | 1.00 | CA1 (0.59) | CA1ACE2EPHX1FFAR1FFAR4 | |
| SCHEMBL7712209 | 1.00 | CA1 (0.59) | CA1ACE2EPHX1FFAR1FFAR4 | |
| SCHEMBL10934322 | 1.00 | CA1 (0.59) | CA1ACE2EPHX1FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111491930-B | Substituted Indole Compounds Useful as TLR Inhibitors | 百时美施贵宝公司 | 2023-09-26 | — | — | CN | claimed |
| CN-116648451-A | Antagonist compounds | 阿道尔克斯治疗有限公司 | 2023-08-25 | — | — | CN | claimed |
| CN-116635380-A | PPARgamma modulators and methods of use | 卫材R&D管理有限公司 | 2023-08-22 | — | — | CN | claimed |
| CN-109311819-B | Isoquinolin-3-yl carboxamides, their preparation and their use | 萨穆梅德有限公司 | 2022-10-25 | — | — | CN | claimed |
| CN-113549006-A | Amide derivative and application thereof | 江苏恩华药业股份有限公司 | 2021-10-26 | — | — | CN | claimed |
| CN-107619950-B | Extraction composition, extraction system and application thereof | 中国科学院上海有机化学研究所 | 2021-04-20 | — | — | CN | claimed |
| EP-3753926-A1 | SPIRO COMPOUND AS INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2020-12-23 | — | — | EP | claimed |
| CN-111699174-A | Spiro compound used as indoleamine-2, 3-dioxygenase inhibitor | 中国科学院上海有机化学研究所 | 2020-09-22 | — | — | CN | claimed |
| CN-111491930-A | Substituted indole compounds useful as T L R inhibitors | 百时美施贵宝公司 | 2020-08-04 | — | — | CN | claimed |
| CN-106103439-A | 2,7 diaza spiros [3.5] nonane compound | 瑞敏德股份有限公司 | 2016-11-09 | — | — | CN | claimed |
| US-20260035335-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250313524-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-10-09 | — | — | US | disclosed |
| EP-4522583-A2 | PI3K ALPHA INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-118085014-A | Preparation method of minoxidil | 和德化学(苏州)有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-114621243-B | Sulfonamide derivative and application thereof | 上海拓界生物医药科技有限公司 | 2024-03-01 | — | — | CN | disclosed |
| WO-1998008850-A1 | SPIROCYCLIC METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 1998-03-05 | — | — | WO | disclosed |
| US-5716477-A | CONSISTS OF A SUPPORT AND THERMAL IMAGE TRANSFER INK LAYER FORMED ON SAID SUPPORT CONSISTS OF A COLORING AGENT AND A PLASTICIZER FOR LOWERING MELT VISCOSITY OF THE RESIN, HIGH THERMOSENSITIVITY ON CLOTH, PLASTIC, OR PAPER RECEIVER | RICOH COMPANY, LTD. (JP) | 1998-02-10 | — | — | US | disclosed |
| US-4575734-A | LEVCO DYES | RICOH COMPANY, LTD. (JP) | 1986-03-11 | — | — | US | disclosed |
| US-4562448-A | Heat-sensitive transfer medium | RICOH CO., LTD. (JP) | 1985-12-31 | — | — | US | disclosed |
| US-4547788-A | SHEET HAVING LAYER CONTAINING LEVCO DYE; ACCEPTOR SHEET CONTAININGCOLORING AGENT; POROUS FILLER | RICOH COMPANY, LTD. (JP) | 1985-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313524-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | PIK3CA, PIK3CB, PIK3CD | CA1 4214/4885ACE2 3019/4885EPHX1 2220/4885 |
| US-20260035335-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | PIK3CD, PIK3CG, PIK3CB | CA1 4595/4885ACE2 4288/4885EPHX1 3889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.